The five commissioners of the Federal Trade Commission voted unanimously Thursday (June 16) to use every tool FTC has to investigate whether drug rebates violate competition and consumer-protection laws. Although the enforcement statement might seem to target pharmacy benefit mangers, commissioners emphasized that they’re putting both PBMs and drug makers on notice. “The agency will use its full range of legal authorities to combat illegal prescription drug practices that foreclose competition and harm patients,” according to a press release on...